翻译元素EIF4A1是结肠癌和直肠癌之间潜在的分歧免疫生物标志物
Zhenpeng Zhu1, Peng Wang2, Chenyang Hou1
1Hebei North University, Zhangjiakou City, Hebei Province, China.
International journal of immunopathology and pharmacology
|November 21, 2025
概括
在结直肠癌中,真核转化启动因子4A1 (EIF4A1) 的上调,与生存率差相关. 它在结肠与直肠癌中的独特作用表明需要量身定制的免疫疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 结肠直肠癌 (CRC) 在全球的发病率很高.
- 识别特定亚型的分子标对于有效的CRC治疗至关重要.
- 细胞转化启动因子4A1 (EIF4A1) 显示出CRC中预后和免疫治疗应用的潜力.
研究的目的:
- 研究EIF4A1在结肠和直肠癌中的作用.
- 探索针对CRC中的EIF4A1的治疗潜力.
- 了解EIF4A1在CRC亚型中的差异表达和功能.
主要方法:
- 定量实时PCR (qRT-PCR) 检测EIF4A1mRNA的表达.
- 针对EIF4A1蛋白水平的免疫组织化学 (IHC).
- 对生物功能和异质性的多维数据库分析.
主要成果:
- 在结肠癌和直肠癌中,EIF4A1被上调,与生存率差相关.
- EIF4A1与中性粒细胞外细胞陷 (NET) 网络和中性粒细胞透相关.
- 观察到不同的免疫透模式:结肠癌中CD8+ T细胞呈阳性,直肠癌中CD4+ T细胞呈阴性.
- 在结肠癌中与免疫检查点分子有强烈的正相关性,在直肠癌中较弱.
结论:
- EIF4A1在结肠癌与直肠癌的进展中表现出异质性和差异性作用.
- 这些发现强调了对CRC的亚型特定免疫治疗策略的必要性.
- 针对EIF4A1可能为个性化CRC治疗提供一种新的方法.
相关概念视频
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...